Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on November 3, 2025. The filing reports on clinical trial progress for the company's investigational product, INTASYL PH-762, specifically within an ongoing Phase 1b dose escalation clinical trial (NCT 06014086) for cutaneous squamous cell carcinoma.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial events and does not contain financial statements or updated financial metrics.
Material Changes and Clinical Results
The primary material event reported is the announcement of clinical trial results at Day 36 for the fifth and final dose cohort:
- Complete Response: 100% tumor clearance observed in one patient.
- Near Complete Response: Greater than 90% tumor reduction observed in a second patient.
- Partial Response: Greater than 50% tumor reduction observed in a third patient.
- Safety Review: The Safety Monitoring Committee issued a favorable review of safety data at the maximum dose of INTASYL PH-762.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, forward-looking projections, or a detailed discussion of risks beyond the standard context of clinical trials. The favorable safety review and positive efficacy data suggest a positive outlook for the advancement of INTASYL PH-762, though no specific timeline for future phases or regulatory submissions is detailed in this text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed patient demographics and statistical significance.
- Confirm the specific criteria used by the Safety Monitoring Committee for the "favorable review" of safety data.
- Review the clinical trial protocol (NCT 06014086) to understand the total number of patients in the final dose cohort versus the number reporting responses.
- Check subsequent filings for updates on the transition from Phase 1b to Phase 2 or further development plans.